Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 15/20 | 0.59 |
| ▸ | CNR2 | P34972 | 8/20 | 0.59 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | ESD | P10768 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.38 |
| ▸ | DRD4 | P21917 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3680872 | 0.85 | CNR1 (0.56) | CNR1CNR2 | |
| Hydrochloric Acid SCHEMBL3557985 | 0.84 | CNR1 (0.56) | CNR1CNR2KIF11ESDDRD2 | |
| SCHEMBL3569818 | 0.80 | CNR1 (0.68) | CNR1CNR2 | |
| SCHEMBL3562281 | 0.78 | CNR1 (0.72) | CNR1CNR2 | |
| SCHEMBL13313062 | 0.78 | CNR1 (0.72) | CNR1CNR2 | |
| SCHEMBL31429978 | 0.78 | ALDH1A1 (0.57) | CNR1CNR2KIF11 | |
| SCHEMBL4605360 | 0.76 | CNR1 (0.59) | CNR1CNR2 | |
| SCHEMBL1748630 | 0.76 | CNR1 (0.65) | CNR1CNR2KIF11 | |
| SCHEMBL1748655 | 0.76 | CNR1 (0.65) | CNR1CNR2KIF11 | |
| SCHEMBL31589469 | 0.76 | CNR1 (0.65) | CNR1CNR2KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763607-B2 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-07-27 | — | — | US | claimed |
| EP-2012775-A1 | USE OF CBX CANNABINOID RECEPTOR MODULATORS AS POTASSIUM CHANNEL MODULATORS | Solvay Pharmaceuticals GmbH (DE) | 2009-01-14 | — | — | EP | claimed |
| WO-2007125049-A1 | USE OF CBX CANNABINOID RECEPTOR MODULATORS AS POTASSIUM CHANNEL MODULATORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-08 | — | — | WO | claimed |
| US-20070254863-A1 | Use of CBx cannabinoid receptor modulators as potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | claimed |
| US-20070254862-A1 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | claimed |
| US-7763607-B2 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-07-27 | — | — | US | disclosed |
| EP-2026798-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CBX CANNABINOID RECEPTOR MODULATORS AND POTASSIUM CHANNEL MODULATORS | Solvay Pharmaceuticals GmbH (DE) | 2009-02-25 | — | — | EP | disclosed |
| EP-2012775-A1 | USE OF CBX CANNABINOID RECEPTOR MODULATORS AS POTASSIUM CHANNEL MODULATORS | Solvay Pharmaceuticals GmbH (DE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007125048-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CBX CANNABINOID RECEPTOR MODULATORS AND POTASSIUM CHANNEL MODULATORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125049-A1 | USE OF CBX CANNABINOID RECEPTOR MODULATORS AS POTASSIUM CHANNEL MODULATORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-08 | — | — | WO | disclosed |
| US-20070254863-A1 | Use of CBx cannabinoid receptor modulators as potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
| US-20070254862-A1 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254863-A1 | Use of CBx cannabinoid receptor modulators as potassium channel modulators | CNR2, CNR1, KCNN1 | CNR1 2/4885CNR2 1/4885KIF11 2062/4885 |
| US-20070254862-A1 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | CNR1, CNR2, KCNJ11 | CNR1 1/4885CNR2 2/4885KIF11 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.